Editing GSK plc (section)

===2011–2022===
In 2011, in a US$660-million deal, [[Prestige Brands|Prestige Brands Holdings]] took over 17 GSK brands with sales of US$210{{nbsp}}million, including [[BC Powder]], [[Beano (dietary supplement)|Beano]], [[Ecotrin]], Fiber Choice, [[Goody's Powder]], [[Sominex]] and [[Tagamet]].<ref>{{cite news |url=http://blogs.newsobserver.com/business/gsk-sells-bc-goodys-and-other-brands |work=News & Observer |last=Ranii |first=David |title=GSK sells BC, Goody's and other brands |date=21 December 2011 |url-status=dead |archive-url=https://web.archive.org/web/20120415192244/http://blogs.newsobserver.com/business/gsk-sells-bc-goodys-and-other-brands |archive-date=15 April 2012}}</ref> In 2012, the company announced that it would invest £500{{nbsp}}million in manufacturing facilities in [[Ulverston]], northern England, designating it as the site for a previously announced biotech plant.<ref>{{Cite news |date=22 March 2012 |title=GSK confirms 500 mln stg UK investment plans |language=en |work=Reuters |url=https://www.reuters.com/article/glaxosmithkline-britain-idUSWLA506520120322 |url-status=live |access-date=10 September 2023 |archive-url=https://web.archive.org/web/20230405074247/https://www.reuters.com/article/glaxosmithkline-britain-idUSWLA506520120322 |archive-date=5 April 2023}}</ref> In May that year it acquired CellZome, a German biotech company, for US$98{{nbsp}}million,<ref>European Biotechnology News 16 May 2012. [http://www.european-biotechnology-news.com/news/news/2012-02/gsk-acquires-cellzome-100.html GSK acquires Cellzome 100%: Britain's largest drugmaker GlaxoSmithKline will pay about €75m in cash to acquire Cellzome AG completely] {{Webarchive|url=https://web.archive.org/web/20160604083405/http://www.european-biotechnology-news.com/news/news/2012-02/gsk-acquires-cellzome-100.html |date=4 June 2016 }}; John Carroll for FierceBiotech 15 May 2012 [http://www.fiercebiotech.com/story/gsk-snags-proteomics-platform-tech-98m-cellzome-buyout/2012-05-15 GSK snags proteomics platform tech in $98M Cellzome buyout]</ref> and in June, worldwide rights to [[alitretinoin]] (Toctino), an [[eczema]] drug, for US$302{{nbsp}}million.<ref>John Carroll for FiercePharma. 12 June 2012 [http://www.fiercebiotech.com/story/gsk-continues-deal-spree-302m-deal-eczema-drug/2012-06-12 GSK continues deal spree with $302M pact for Basilea eczema drug] {{Webarchive|url=https://web.archive.org/web/20140529051425/http://www.fiercebiotech.com/story/gsk-continues-deal-spree-302m-deal-eczema-drug/2012-06-12 |date=29 May 2014 }}; Basilea Pharmaceutica Press Release. 11 June 2012 [http://hugin.info/134390/R/1618919/516985.pdf Basilea enters into global agreement with Stiefel, a GSK company, for Toctino (alitretinoin)]</ref> In 2013, GSK acquired [[Human Genome Sciences]] (HGS) for US$3{{nbsp}}billion; the companies had collaborated on developing the [[lupus]] drug [[Belimumab]] (Benlysta), [[albiglutide]] for [[type 2 diabetes]], and [[darapladib]] for [[atherosclerosis]],<ref name="3Lessons">{{Cite web |last=Herper |first=Matthew |date=16 July 2012 |title=Three Lessons From GlaxoSmithKline's Purchase Of Human Genome Sciences |url=https://www.forbes.com/sites/matthewherper/2012/07/16/three-lessons-from-glaxosmithklines-purchase-of-human-genome-sciences/ |url-status=live |archive-url=https://archive.today/20140527183210/http://www.forbes.com/sites/matthewherper/2012/07/16/three-lessons-from-glaxosmithklines-purchase-of-human-genome-sciences/ |archive-date=27 May 2014 |access-date=10 September 2023 |website=Forbes |language=en}}</ref> and in September, sold its beverage division to [[Suntory]]. This included the brands [[Lucozade]] and [[Ribena]]; however, the deal did not include [[Horlicks]].<ref name="Monaghan">{{Cite news |last=Monaghan |first=Angela |date=9 September 2013 |title=Ribena and Lucozade sold to Japanese drinks giant |language=en-GB |work=The Guardian |url=https://www.theguardian.com/business/2013/sep/09/ribena-lucozade-sold-japan-glaxosmithkline |url-status=live |access-date=10 September 2023 |archive-url=https://web.archive.org/web/20230405015039/https://www.theguardian.com/business/2013/sep/09/ribena-lucozade-sold-japan-glaxosmithkline |archive-date=5 April 2023 |issn=0261-3077}}</ref>

In March 2014, GSK paid US$1{{nbsp}}billion to raise its stake in its Indian pharmaceutical unit, [[GlaxoSmithKline Pharmaceuticals]], to 75 per cent as part of a move to focus on emerging markets.<ref>{{cite news |last=Hirschler |first=Ben |date=10 March 2014 |title=GSK pays $1&nbsp;billion to lift Indian unit stake to 75 percent |work=Reuters |url=https://www.reuters.com/article/us-glaxosmithkline-india-idUSBREA2909U20140310 |url-status=live |access-date=10 March 2014 |archive-url=https://web.archive.org/web/20230405080005/https://www.reuters.com/article/us-glaxosmithkline-india-idUSBREA2909U20140310 |archive-date=5 April 2023}}</ref> In April 2014, Novartis and Glaxo agreed on more than US$20{{nbsp}}billion in deals, with Novartis selling its vaccine business to GSK and buying GSK's cancer business.<ref>{{cite news |last1=Bray |first1=Chad |last2=Jolly |first2=David |date=23 April 2014 |title=Novartis and Glaxo Agree to Trade $20 Billion in Assets |website=[[The New York Times]] |url=https://dealbook.nytimes.com/2014/04/22/novartis-announces-major-restructuring/ |url-status=live |access-date=12 March 2020 |archive-url=https://web.archive.org/web/20230405080005/https://archive.nytimes.com/dealbook.nytimes.com/2014/04/22/novartis-announces-major-restructuring/ |archive-date=5 April 2023}}</ref><ref name="wsj4222014">{{cite news |last1=Rockoff |first1=Jonathan D. |last2=Whalen |first2=Jeanne |last3=Falconi |first3=Marta |date=22 April 2014 |title=Deal Flurry Shows Drug Makers' Swing Toward Specialization |website=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/deal-flurry-shows-drug-makers-swing-toward-specialization-1398214581 |url-status=live |url-access=subscription |access-date=12 March 2020 |archive-url=https://archive.today/20230910233717/https://www.wsj.com/amp/articles/deal-flurry-shows-drug-makers-swing-toward-specialization-1398214581 |archive-date=10 September 2023}}</ref> In February 2015, GSK announced that it would acquire GlycoVaxyn, a Swiss pharmaceutical company, for US$190{{nbsp}}million,<ref>{{cite web |date=11 February 2015 |title=GEN - News Highlights:GSK Acquires GlycoVaxyn for $190M |url=http://www.genengnews.com/gen-news-highlights/gsk-acquires-glycovaxyn-for-190m/81250916/ |archive-url=https://web.archive.org/web/20230403180134/https://www.genengnews.com/ |archive-date=3 April 2023 |work=GEN}}</ref> and in June that year that it would sell two [[meningitis]] drugs to [[Pfizer]], Nimenrix and [[Mencevax]] for around US$130{{nbsp}}million.<ref>{{cite web |date=22 June 2015 |title=Pfizer Buys Two GSK Meningitis Vaccines for $130M |url=http://www.genengnews.com/gen-news-highlights/pfizer-buys-two-gsk-meningitis-vaccines-for-130m/81251415/ |archive-url=https://web.archive.org/web/20230331181324/https://www.genengnews.com/topics/drug-discovery/pfizer-buys-two-gsk-meningitis-vaccines-for-130m/ |archive-date=31 March 2023 |access-date=25 March 2016 |work=GEN}}</ref>

[[Philip Hampton]], at that time chair of the [[Royal Bank of Scotland]], became GSK chairman in September 2015.<ref>{{Cite web |last=Quinn |first=James |date=25 September 2014 |title=Sir Philip Hampton to chair Glaxo |url=https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11120385/Sir-Philip-Hampton-to-chair-Glaxo.html |url-status=live |archive-url=https://web.archive.org/web/20230404113206/https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/11120385/Sir-Philip-Hampton-to-chair-Glaxo.html |archive-date=4 April 2023 |access-date=10 September 2023 |website=The Telegraph |language=en}}</ref>

On 31 March 2017, [[Emma Walmsley]] became [[Chief executive officer|CEO]]. She is the first female CEO of the company.<ref>{{Cite news |last=Herper |first=Matthew |title=GlaxoSmithKline Appoints Big Pharma's First Woman Chief Executive |work=Forbes |url=https://www.forbes.com/sites/matthewherper/2016/09/20/glaxosmithkline-appoints-big-pharmas-first-woman-chief-executive/#7f8a02ca3276 |url-status=live |access-date=11 December 2017 |archive-url=https://archive.today/20230910234224/https://www.forbes.com/sites/matthewherper/2016/09/20/glaxosmithkline-appoints-big-pharmas-first-woman-chief-executive/?sh=149dee932769 |archive-date=10 September 2023}}</ref><ref name=successionAWtoEW>{{cite news |url=https://www.telegraph.co.uk/business/2016/09/20/glaxosmithkline-names-emma-walmsley-to-replace-sir-andrew-witty/ |archive-url=https://web.archive.org/web/20160921225245/http://www.telegraph.co.uk/business/2016/09/20/glaxosmithkline-names-emma-walmsley-to-replace-sir-andrew-witty/ |archive-date=21 September 2016 |url-access=subscription |url-status=live |title=Emma Walmsley becomes latest female CEO in FTSE 100 as she replaces Sir Andrew Witty at GSK |last=Yeomans |first=Jon |newspaper=The Telegraph |publisher=Daily Telegraph, London |date=20 September 2016 |access-date=20 September 2016}}</ref>

In December 2017, Reuters reported that Glaxo had increased its stake in its Saudi Arabian unit to 75% (from 49%) taking over control from its Saudi partner Banaja KSA Holding Company.<ref>{{cite news |date=18 December 2017 |title=GlaxoSmithKline boosts stake in Saudi Arabia unit |newspaper=Reuters |url=https://www.reuters.com/article/gsk-saudi/glaxosmithkline-boosts-stake-in-saudi-arabia-unit-idUSL8N1OI1Q4 |url-status=live |archive-url=https://web.archive.org/web/20230404145936/https://www.reuters.com/article/gsk-saudi/glaxosmithkline-boosts-stake-in-saudi-arabia-unit-idUSL8N1OI1Q4 |archive-date=4 April 2023}}</ref>

With respect to [[rare disease]]s, the company divested its portfolio of [[gene therapy]] drugs to Orchard Therapeutics in April 2018.<ref name=":0" /> In November 2018, [[Reuters]] reported that [[Unilever]] was in prime position to acquire GSK's interest in its Indian unit, GlaxoSmithKline Consumer Healthcare Ltd, in a sale that could generate around US$4{{nbsp}}billion for the company.<ref name="pole">{{cite news |last1=Gruber |first1=Kane Wu |date=28 November 2018 |title=Unilever in pole position to swallow GSK's Indian Horlicks business |newspaper=Reuters |url=https://uk.reuters.com/article/uk-gsk-m-a-india/nestl-unilever-in-pole-position-for-gsks-indian-horlicks-business-reports-idUKKCN1NX0F0 |url-status=dead |access-date=28 November 2018 |archive-url=https://web.archive.org/web/20181128071040/https://uk.reuters.com/article/uk-gsk-m-a-india/nestl-unilever-in-pole-position-for-gsks-indian-horlicks-business-reports-idUKKCN1NX0F0 |archive-date=28 November 2018}}</ref> [[Nestlé]] and [[Coca-Cola]] have also been reported to be interested in the business unit as they look to strengthen their presence in India.<ref name=pole/><ref>{{cite web |last=Sagonowsky |first=Eric |date=28 November 2018 |title=GlaxoSmithKline taps Unilever as lead bidder in Indian Horlicks buyout: report |url=https://www.fiercepharma.com/pharma/unilever-gsk-late-stage-talks-for-horlicks-buyout-india-reuters |url-status=live |archive-url=https://web.archive.org/web/20230405015037/https://www.fiercepharma.com/pharma/unilever-gsk-late-stage-talks-for-horlicks-buyout-india-reuters |archive-date=5 April 2023 |access-date=28 November 2018 |publisher=FiercePharma}}</ref> On 3 December 2018, GSK announced that Unilever would acquire the Indian-listed GlaxoSmithKline Consumer Healthcare business for US$3.8{{nbsp}}billion (£2.98{{nbsp}}billion). Unilever will pay the majority of the deal in cash, with the remaining being paid in shares in its Indian operation, [[Hindustan Unilever|Hindustan Unilever Limited]]. Upon completion, GSK will then own around 5.7% of Hindustan Unilever Limited, selling those shares in a number of tranches.<ref>{{cite news |date=3 December 2018 |title=Unilever swallows GSK's Indian Horlicks business for $3.8&nbsp;billion |work=Reuters |url=https://uk.reuters.com/article/uk-gsk-m-a-unilever/unilever-swallows-gsks-indian-horlicks-business-for-3-8-billion-idUKKBN1O20P3 |url-status=dead |access-date=3 December 2018 |archive-url=https://web.archive.org/web/20181203114000/https://uk.reuters.com/article/us-gsk-m-a-unilever/unilever-swallows-gsks-indian-horlicks-business-for-3-8-billion-idUKKBN1O20S7 |archive-date=3 December 2018}}</ref> The same day, the company also announced it would acquire oncology specialist, [[Tesaro]], for US$5.1{{nbsp}}billion. The deal will give GSK control of ovarian cancer treatment, [[Zejula]] - a member of the class of [[poly ADP ribose polymerase]] (PARP) inhibitors.<ref>{{cite news |last=Hirschler |first=Ben |date=3 December 2018 |title=GSK slides after buying cancer firm Tesaro for hefty $5.1&nbsp;billion |work=Reuters |url=https://uk.reuters.com/article/us-tesaro-m-a-gsk/gsk-slides-after-buying-cancer-firm-tesaro-for-hefty-5-1-billion-idUKKBN1O218H |url-status=dead |access-date=3 December 2018 |archive-url=https://web.archive.org/web/20181203161201/https://uk.reuters.com/article/uk-tesaro-m-a-gsk/gsk-slides-after-buying-cancer-firm-tesaro-for-hefty-5-1-billion-idUKKBN1O218B |archive-date=3 December 2018}}</ref>

In October 2019, GSK agreed to sell its [[rabies]] vaccine, [[RabAvert]], and its [[tick-borne encephalitis]] vaccine, [[Encepur]], to [[Bavarian Nordic]] for US$1.06{{nbsp}}billion (€955{{nbsp}}million).<ref>{{Cite web |url=https://www.fiercepharma.com/vaccines/gsk-sells-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic-for-up-to-1-06b |title=Zeroing in on fast-growing vaccines, GSK sheds 2 shots to Bavarian Nordic for up to $1.1B |last=Sagonowsky |first=Eric |date=21 October 2019 |website=FiercePharma |url-status=live |archive-url=https://web.archive.org/web/20200105160030/https://www.fiercepharma.com/vaccines/gsk-sells-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic-for-up-to-1-06b |archive-date=5 January 2020 |access-date=26 January 2020}}</ref><ref>{{Cite web |date=21 October 2019 |title=GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic |url=https://www.gsk.com/en-gb/media/press-releases/gsk-agrees-to-divest-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic/ |url-status=live |archive-url=https://web.archive.org/web/20230804142613/https://www.gsk.com/en-gb/media/press-releases/gsk-agrees-to-divest-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic/ |archive-date=4 August 2023 |access-date=26 January 2020 |website=GSK }}</ref>

In July 2020, GSK acquired a 10% stake in German biotech company [[CureVac]].<ref>{{Cite news |last1=Schuetze |first1=Arno |last2=Aripaka |first2=Pushkala |date=20 July 2020 |title=GSK buys 10% of CureVac in vaccine tech deal |newspaper=Reuters |url=https://uk.reuters.com/article/us-gsk-curevac-stake-idUKKCN24L0JR |url-status=dead |archive-url=https://web.archive.org/web/20200720223837/https://uk.reuters.com/article/us-gsk-curevac-stake-idUKKCN24L0JR |archive-date=20 July 2020 |via=uk.reuters.com}}</ref>

==== GSK–Novartis consumer healthcare buy-out ====
In March 2018, GSK announced that it has reached an agreement with [[Novartis]] to acquire Novartis's 36.5% stake in their Consumer Healthcare Joint Venture for US$13{{nbsp}}billion (£9.2{{nbsp}}billion).<ref>{{cite news |last=Shields |first=Michael |date=27 March 2018 |title=GSK buys out Novartis in $13&nbsp;billion consumer healthcare shake-up |work=Reuters |url=https://uk.reuters.com/article/us-novartis-gsk/gsk-buys-out-novartis-in-13-billion-consumer-healthcare-shake-up-idUKKBN1H30FK |url-status=deviated |access-date=27 March 2018 |archive-url=https://web.archive.org/web/20180327111340/https://uk.reuters.com/article/us-novartis-gsk/gsk-buys-out-novartis-in-13-billion-consumer-healthcare-shake-up-idUKKBN1H30FK |archive-date=27 March 2018}}</ref><ref name=":0">{{Cite news |last=<!--no byline--> |date=21 July 2018 |title=GlaxoSmithKline considers splitting up the group - FT |work=Reuters |url=https://in.reuters.com/article/gsk-divestiture/glaxosmithkline-considers-splitting-up-the-group-ft-idINKBN1KB07N |url-status=dead |access-date=23 July 2018 |archive-url=https://web.archive.org/web/20180721085717/https://in.reuters.com/article/gsk-divestiture/glaxosmithkline-considers-splitting-up-the-group-ft-idINKBN1KB07N |archive-date=21 July 2018}}</ref>

==== GSK–Pfizer joint venture ====
In December 2018, GSK announced that it, along with [[Pfizer]], had reached an agreement to merge and combine their consumer healthcare divisions into a single entity. The combined entity would have sales of around £9.8{{nbsp}}billion ($12.7{{nbsp}}billion), with GSK maintaining a 68% controlling stake in the joint venture. Pfizer would own the remaining 32% shareholding. The deal builds on an earlier 2018 deal where GSK bought out Novartis' stake in the GSK-Novartis consumer healthcare joint business.<ref name="split">{{cite news |last=Hirschler |first=Ben |date=19 December 2018 |title=Drugmaker GSK to split after striking Pfizer consumer health deal |work=Reuters |url=https://uk.reuters.com/article/us-pfizer-m-a-gsk/drugmaker-gsk-to-split-after-striking-pfizer-consumer-health-deal-idUKKBN1OI0IP |url-status=deviated |access-date=19 December 2018 |archive-url=https://web.archive.org/web/20181219125857/https://uk.reuters.com/article/uk-pfizer-m-a-gsk/drugmaker-gsk-to-split-after-striking-pfizer-consumer-health-deal-idUKKBN1OI0IN |archive-date=19 December 2018}}</ref>

==== Subsequent split ====
[[File:GSK logo 2014.svg|thumb|100px|Prior logo before 9 June 2022]]
The culmination of the Consumer Healthcare string of deals will result in GSK splitting into two separate companies, via a demerger and subsequent listing of the joint venture. This will create two publicly traded companies, one focusing on pharmaceuticals and research & development, the other on consumer healthcare. On 22 February 2022, GSK announced that the spin-off consumer healthcare company will be called [[Haleon]].<ref name=split/><ref>{{cite news |last=Freeman |first=Simon |date=22 February 2022 |title=Hello, Haleon: GlaxoSmithKline reveals name of £60bn consumer health spin-out |newspaper=Evening Standard |url=https://www.standard.co.uk/business/glaxosmithkline-gsk-names-spinoff-haleon-sensodyne-walmsley-elliott-b983928.html |url-status=live |access-date=23 February 2022 |archive-url=https://web.archive.org/web/20230405015033/https://www.standard.co.uk/business/glaxosmithkline-gsk-names-spinoff-haleon-sensodyne-walmsley-elliott-b983928.html |archive-date=5 April 2023}}</ref>

In January 2022, the company announced that they had received three unsolicited offers from [[Unilever]] to acquire the Consumer Healthcare business unit, with the final proposal valuing the business unit at £50 billion (£41.7 billion in cash, plus £8.3 billion in Unilever shares).<ref>{{Cite news |last1=Cavale |first1=Siddharth |last2=Burger |first2=Ludwig |last3=Dey |first3=Mrinmay |date=15 January 2022 |title=GSK rejects 50-billion-pound Unilever offer for consumer assets |newspaper=Reuters |url=https://www.reuters.com/business/retail-consumer/unilever-offers-50-bln-pounds-gsk-unit-report-2022-01-15/ |archive-url=https://web.archive.org/web/20220115110019/https://www.reuters.com/business/retail-consumer/unilever-offers-50-bln-pounds-gsk-unit-report-2022-01-15/ |archive-date=15 January 2022 |via=www.reuters.com}}</ref>

Subsequently, GSK declined all outside offers/attempts to acquire its consumer healthcare business and moved forward with its plan to complete the demerger from the main biopharmaceutical business.<ref>{{Cite web |url=https://www.ft.com/content/85f28cd9-ca18-4f2b-8346-c22efdfe1382 |archive-url=https://ghostarchive.org/archive/20221210/https://www.ft.com/content/85f28cd9-ca18-4f2b-8346-c22efdfe1382 |archive-date=10 December 2022 |url-access=subscription |title=Pfizer to exit GSK consumer health joint venture after London listing |newspaper=Financial Times |date=1 June 2022 |access-date=15 June 2022}}</ref>